{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:00:58Z","timestamp":1793746858471,"version":"4.6.1"},"reference-count":78,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>Discovered in the 1960s, the common anthelminthic levamisole has seen widespread use in veterinary applications. Its use rapidly expanded thereafter to include human medical treatments for a variety of acute and chronic disorders. Because of reports of severe adverse effects, the US Food and Drug Administration withdrew levamisole's approval for human use in 2000; however, medical options outside the United States and illicit options worldwide allow continued accessibility to levamisole. The compound is rapidly metabolized in the body, with at least 2 known active metabolites. Levamisole has a broad range of immunomodulatory effects, including both stimulatory and inhibitory effects on immune responses. It is generally well tolerated at therapeutic concentrations, although a variety of autoimmune-related adverse effects have been reported, including agranulocytosis, leukopenia, purpura, and visible necrotized skin tissue. Individuals with levamisole-compromised immune systems are more susceptible to infections, including COVID-19. Since the early 2000's, levamisole has been frequently used as an adulterating agent in illicit street drugs, especially cocaine, fentanyl, and heroin. Although its prevalence has varied over time and geographically, levamisole has been detected in up to 79% of the street supply of cocaine at levels up to 74% by weight. Its presence in illicit drug markets also raises concern over the potential for exposure of children and neonates, although this is supported by only limited anecdotal evidence. Levamisole is not currently included in routine drug testing panels, although a variety of confirmatory testing techniques exist across a range of antemortem and postmortem specimen options. Because of its varying presence in illicit drug markets, both the medical and forensic communities need to be aware of levamisole and its potential impact on toxicological investigations.<\/jats:p>","DOI":"10.1097\/ftd.0000000000000851","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T20:26:45Z","timestamp":1607632005000},"page":"221-228","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":43,"title":["Levamisole\u2014a Toxic Adulterant in Illicit Drug Preparations: a Review"],"prefix":"10.1097","volume":"43","author":[{"given":"Kari M.","family":"Midthun","sequence":"first","affiliation":[{"name":"NMS Labs, Horsham, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis S.","family":"Nelson","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Rutgers New Jersey Medical School, Newark, New Jersey; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry K.","family":"Logan","sequence":"additional","affiliation":[{"name":"NMS Labs, Horsham, Pennsylvania;"},{"name":"Center for Forensic Science Research and Education (CFSRE) at the Fredric Rieders Family Foundation, Willow Grove, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3109\/15563650.2012.665455","article-title":"Levamisole in cocaine: unexpected news from an old acquaintance","volume":"50","author":"Larocque","year":"2012","journal-title":"Clin Toxicol."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.mayocp.2012.03.010","article-title":"Complications associated with use of levamisole-contaminated cocaine: an emerging public health challenge","volume":"87","author":"Lee","year":"2012","journal-title":"Mayo Clin Proc."},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/clpt.2010.156","article-title":"Levamisole: a dangerous new cocaine adulterant","volume":"88","author":"Chang","year":"2010","journal-title":"Clin Pharmacol Ther."},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/1556-4029.13968","article-title":"Detection of cutting agents in drug-positive seized exhibits within the United States","volume":"64","author":"Fiorentin","year":"2019","journal-title":"J Forensic Sci."},{"key":"R5-20250603","first-page":"1381","article-title":"Agranulocytosis associated with cocaine use\u2014four states, March 2008\u2014November 2009","volume":"58","year":"2009","journal-title":"Morb Mortal Wkly Rep."},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/jat\/bkr025","article-title":"Determination of Phenyltetrahydroimidazothiazole enantiomers (Levamisole\/Dexamisole) in illicit cocaine seizures and in the urine of cocaine abusers via chiral capillary gas chromatography-flame ionization detection: clinical and forensic perspectives","volume":"36","author":"Casale","year":"2012","journal-title":"J Anal Toxicol."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1124\/dmd.112.045021","article-title":"Immune-mediated agranulocytosis caused by the cocaine adulterant levamisole: a case for reactive metabolite(s) involvement","volume":"40","author":"Wolford","year":"2012","journal-title":"Drug Metab Dispos."},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3390\/jcm8060860","article-title":"Levamisole in children with idiopathic nephrotic syndrome: clinical efficacy and pathophysiological aspects","volume":"8","author":"Muhlig","year":"2019","journal-title":"J Clin Med."},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2165\/00128071-200405020-00004","article-title":"Levamisole in dermatology","volume":"5","author":"Scheinfeld","year":"2004","journal-title":"Am J Clin Dermatol."},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"230","DOI":"10.4103\/0378-6323.175927","article-title":"Levamisole: a multi-faceted drug in dermatology","volume":"82","author":"Gupta","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol."},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2165\/00003088-198815020-00001","article-title":"Clinical pharmacokinetics of anthelmintic drugs","volume":"15","author":"Edwards","year":"1988","journal-title":"Clin Pharmacokinet."},{"key":"R16-20250603","first-page":"397","article-title":"Modulation of immunity by levamisole","volume":"2","author":"Renoux","year":"1978","journal-title":"Pharmacol Ther."},{"key":"R17-20250603","first-page":"137","article-title":"Pharmacokinetics of levamisole","volume":"4","author":"Adams","year":"1978","journal-title":"J Rheumatol."},{"key":"R18-20250603","first-page":"235","article-title":"Pharmacokinetic studies on levamisole on the pharmacokinetics and relative bioavailability of levamisole in man","volume":"2","author":"Graziani","year":"1977","journal-title":"Drugs Exp Clin Res."},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/bdd.2510070110","article-title":"Novel assay and pharmacokinetics of levamisole and p-hydroxylevamisole in human plasma and urine","volume":"7","author":"Kouassi","year":"1986","journal-title":"Biopharm Drug Dispos."},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/BF03189626","article-title":"Pharmacokinetics of levamisole in healthy subjects and cancer patients","volume":"7","author":"Luyckx","year":"1982","journal-title":"Eur J Drug Metab Pharmacokinet."},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s002800050770","article-title":"Clinical and pharmacokinetic studies of high-dose levamisole in combination with 5-fluorouracil in patients with advanced cancer","volume":"41","author":"Reid","year":"1998","journal-title":"Cancer Chemother Pharmacol."},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.aca.2006.03.068","article-title":"Pharmacokinetics and brain distribution of unbound levamisole in the anesthetized rats using microdialysis and microbore column liquid chromatography","volume":"569","author":"Lin","year":"2006","journal-title":"Anal Chim Acta."},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.aca.2009.02.033","article-title":"Aminorex and rexamino as metabolites of levamisole in the horse","volume":"638","author":"Ho","year":"2009","journal-title":"Anal Chim Acta."},{"key":"R24-20250603","first-page":"347","article-title":"The levamisole story","volume":"20","author":"Janssen","year":"1976","journal-title":"Prog Drug Res."},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1186\/2046-0481-63-8-498","article-title":"Pemoline and tetramisole positives in English racehorses following levamisole administration","volume":"63","author":"Gutierrez","year":"2010","journal-title":"Ir Vet J."},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1007\/s00216-013-6829-x","article-title":"Metabolism of levamisole and kinetics of levamisole and aminorex in urine by means of LC-QTOF-HRMS and LC-QqQ-MS","volume":"405","author":"Hess","year":"2013","journal-title":"Anal Bioanal Chem."},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1365-2885.2008.01015.x","article-title":"The formation of aminorex in racehorses following levamisole administration. A quantitative and chiral analysis following synthetic aminorex or levamisole administration vs. aminorex-positive samples from the field: a preliminary report","volume":"32","author":"Barker","year":"2009","journal-title":"J Vet Pharmacol Ther."},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/dta.1619","article-title":"Determination of levamisole, aminorex, and pemoline in plasma by means of liquid chromatography-mass spectrometry and application to a pharmacokinetic study of levamisole","volume":"6","author":"Hess","year":"2014","journal-title":"Drug Test Anal."},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.forsciint.2014.03.028","article-title":"Aminorex associated with possible idiopathic pulmonary hypertension in a cocaine user","volume":"240","author":"Karch","year":"2014","journal-title":"Forensic Sci Int."},{"key":"R32-20250603","first-page":"472","article-title":"Cocaine adulteration with the anthelmintic tetramisole (levamisole\/dexamisole): long-term monitoring of its intake by chiral LC-MS\/MS analysis of cocaine-positive hair samples","volume":"1","author":"Madry","year":"2018","journal-title":"Drug Test Anal."},{"key":"R33-20250603","first-page":"173","article-title":"Analysis of adulterants from cocaine preparations in lung tissue and blood","volume":"82","author":"Pawlik","year":"2015","journal-title":"Toxichem Krimtech."},{"key":"R34-20250603","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.forsciint.2015.02.006","article-title":"Drug-related death: adulterants from cocaine preparations in lung tissue and blood","volume":"249","author":"Pawlik","year":"2015","journal-title":"Forensic Sci Int."},{"key":"R35-20250603","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1093\/jat\/33.9.620","article-title":"The possible role of levamisole in illicit cocaine preparations","volume":"33","author":"Raymon","year":"2009","journal-title":"J Anal Toxicol."},{"key":"R36-20250603","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.pt.2012.04.003","article-title":"Levamisole receptors: a second awakening","volume":"28","author":"Martin","year":"2012","journal-title":"Trends Parasitol."},{"key":"R38-20250603","first-page":"288","article-title":"Potentiation of T-cell mediated immunity by levamisole","volume":"25","author":"Renoux","year":"1976","journal-title":"Clin Exp Immunol."},{"key":"R39-20250603","first-page":"119","article-title":"Augmentation of IL12-dependent Th1 cytokine production by levamisole","volume":"9","author":"Holcombe","year":"1997","journal-title":"Allergy Clin Immunol Int."},{"key":"R40-20250603","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10456-005-3588-0","article-title":"Levamisole inhibits angiogenesis in vitro and tumor growth in vivo","volume":"8","author":"Friis","year":"2005","journal-title":"Angiogenesis."},{"key":"R41-20250603","first-page":"71","article-title":"The non-hematological side effects of levamisole in the treatment of rheumatoid arthritis\u2014a review","volume":"4","author":"Pinals","year":"1977","journal-title":"J Rheumatol."},{"key":"R42-20250603","first-page":"262","article-title":"Leukoencephalopathy after levamisole for the treatment of verrucae","volume":"20","author":"Cheng","year":"2011","journal-title":"Acta Neurol Taiwanica."},{"key":"R43-20250603","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.psym.2013.02.012","article-title":"Levamisole: a common cocaine adulterant with life-threatening side effects","volume":"43","author":"Auffenberg","year":"2013","journal-title":"Psychosomatics."},{"key":"R44-20250603","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/MOH.0000000000000393","article-title":"Cocaine\/levamisole-associated autoimmune syndrome: a disease of neutrophil-mediated autoimmunity","volume":"25","author":"Cascio","year":"2018","journal-title":"Curr Opin Hematol."},{"key":"R45-20250603","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMicm1008722","article-title":"Toxic effects of levamisole in a cocaine user","volume":"364","author":"Muirhead","year":"2011","journal-title":"New Engl J Med."},{"key":"R46-20250603","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s10067-011-1805-3","article-title":"A novel cutaneous vasculitis syndrome induced by levamisole-contaminated cocaine","volume":"30","author":"Gross","year":"2011","journal-title":"Clin Rheumatol."},{"key":"R47-20250603","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1002\/PHAR.1012","article-title":"Palpable purpura complicated by streptococcal toxic shock syndrome resulting in limb necrosis and amputation \u2013 a case of levamisole and cocaine coingestion","volume":"32","author":"Freyer","year":"2012","journal-title":"Pharmacotherapy."},{"key":"R48-20250603","first-page":"302","article-title":"Chronic levamisole-induced vasculitis: a case report","volume":"54","author":"Lee","year":"2012","journal-title":"B C Med J."},{"key":"R49-20250603","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3122\/jabfm.2012.04.110177","article-title":"Agranulocytosis from levamisole-adulterated cocaine","volume":"25","author":"Caldwell","year":"2012","journal-title":"J Am Board Fam Med."},{"key":"R51-20250603","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/20009666.2018.1536242","article-title":"Levamisole adulterated cocaine associated ANCA vasculitis: review of literature and update on pathogenesis","volume":"8","author":"Jin","year":"2018","journal-title":"J Community Hosp Intern Med Perspect."},{"key":"R52-20250603","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1007\/s00204-017-1947-4","article-title":"Adverse effects of levamisole in cocaine users: a review and risk assessment","volume":"91","author":"Brunt","year":"2017","journal-title":"Arch Toxicol."},{"key":"R53-20250603","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.forsciint.2018.12.016","article-title":"Determination of cutting agents in seized cocaine samples using GC-MS, GC-TMS and LC-MS\/MS","volume":"295","author":"Fiorentin","year":"2019","journal-title":"Forensic Sci Int."},{"key":"R54-20250603","doi-asserted-by":"crossref","first-page":"e89780","DOI":"10.1172\/jci.insight.89780","article-title":"A role for muscarinic receptors in neutrophil extracelullar trap formation and levamisole-induced autoimmunity","volume":"2","author":"Carmona-Rivera","year":"2017","journal-title":"JCI Insight."},{"key":"R55-20250603","first-page":"638","article-title":"Neutrophil extracellular traps as a potential source of autoantigen in cocaine-associated autoimmunity","volume":"56","author":"Lood","year":"2017","journal-title":"Rheumatology (Oxford)."},{"key":"R56-20250603","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1940-0640-7-19","article-title":"Levamisole-induced leukocytoclastic vasculitis and neutropenia in a patient with cocaine use: an extensive case with necrosis of skin, soft tissue, and cartilage","volume":"7","author":"Arora","year":"2012","journal-title":"Addict Sci Clin Pract."},{"key":"R57-20250603","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1515\/cclm-2012-0519","article-title":"Bioanalytical methods for quantitation of levamisole, a widespread cocaine adulterant","volume":"51","author":"Shea","year":"2013","journal-title":"Clin Chem Lab Med."},{"key":"R58-20250603","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0378-4347(00)80134-6","article-title":"Determination of levamisole in plasma and animal tissues by gas chromatography with thermionic specific detection","volume":"224","author":"Woestenborghs","year":"1981","journal-title":"J Chromatogr."},{"key":"R59-20250603","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/BF03189527","article-title":"Gas-chromatographic determination of levamisole in human plasma \u2013 Normalization and reliability of the method","volume":"6","author":"Rousseau","year":"1981","journal-title":"Eur J Drug Metab Pharmacokinet."},{"key":"R60-20250603","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1039\/an9800500993","article-title":"Determination of the anthelmintic levamisole in plasma and gastro-intestinal fluids by high-performance liquid chromatography","volume":"105","author":"Marriner","year":"1980","journal-title":"Analyst."},{"key":"R61-20250603","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF03226369","article-title":"Quantitation of levamisole in plasma using high performance liquid chromatography","volume":"20","author":"Vandamme","year":"1995","journal-title":"Eur J Drug Metab Pharmacokinet."},{"key":"R62-20250603","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/anatox\/35.8.545","article-title":"Determination of levamisole in urine by gas chromatography-mass spectrometry","volume":"35","author":"Trehy","year":"2011","journal-title":"J Anal Toxicol."},{"key":"R63-20250603","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.jpba.2011.03.039","article-title":"Determination of aminorex in human urine samples by GC-MS after use of levamisole","volume":"55","author":"Bertol","year":"2011","journal-title":"J Pharm Biomed Anal."},{"key":"R64-20250603","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/anatox\/35.3.176","article-title":"Detection of levamisole exposure in cocaine users by liquid chromatography-tandem mass spectrometry","volume":"35","author":"Lynch","year":"2011","journal-title":"J Anal Toxicol."},{"key":"R65-20250603","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jchromb.2010.11.015","article-title":"A sensitive LC-MS\/MS method for determination of levamisole in human plasma: application to pharmacokinetic study","volume":"879","author":"Tong","year":"2011","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R66-20250603","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.jpba.2010.11.043","article-title":"A new mixed mode solid phase extraction strategy for opioids, cocaines, amphetamines, and adulterants in human blood with hybrid liquid chromatography tandem mass spectrometry detection","volume":"54","author":"Dowling","year":"2011","journal-title":"J Pharm Biomed Anal."},{"key":"R67-20250603","first-page":"134","article-title":"Levamisole: an analytical profile","volume":"3","author":"Valentino","year":"2005","journal-title":"Microgram J."},{"key":"R70-20250603","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.pathol.2018.03.006","article-title":"The cocaine cutting agent levamisole is frequently detected in cocaine users","volume":"50","author":"Pope","year":"2018","journal-title":"Pathology"},{"key":"R72-20250603","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.forsciint.2007.05.021","article-title":"Unusual adulterants in cocaine seizured on Italian clandestine market","volume":"172","author":"Fucci","year":"2007","journal-title":"Forensic Sci Int."},{"key":"R73-20250603","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.neuint.2013.11.010","article-title":"Aminorex, a metabolite of the cocaine adulterant levamisole, exerts amphetamine like actions at monoamine transporters","volume":"73","author":"Hofmaier","year":"2014","journal-title":"Neurochem Int."},{"key":"R74-20250603","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.cgh.2020.04.001","article-title":"Diarrhea during COVID-19 infection: pathogenesis, epidemiology, prevention, and management","volume":"18","author":"D'Amico","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"key":"R75-20250603","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.cgh.2020.03.043","article-title":"Don't overlook digestive symptoms in patients with 2019 novel coronavirus disease (COVID-19)","volume":"18","author":"Luo","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"key":"R76-20250603","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet."},{"key":"R77-20250603","first-page":"e203204","article-title":"Epidemiologic features and clinical course of patients infects with SARS-CoV-2 in Singapore","author":"Young","year":"2020","journal-title":"JAMA."},{"key":"R78-20250603","doi-asserted-by":"crossref","first-page":"844","DOI":"10.3855\/jidc.13101","article-title":"Can levamisole be used in the treatment of COVID-19 patients presenting with diarrhea?","volume":"14","author":"Uyaroglu","year":"2020","journal-title":"J Infect Dev Ctries."},{"key":"R82-20250603","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1080\/10550887.2020.1800890","article-title":"Levamisole-adulterated cocaine poses a concern during the COVID-19 pandemic","volume":"38","author":"Marski","year":"2020","journal-title":"J Addict Dis."},{"key":"R83-20250603","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/1097-0142(197903)43:3<1112::AID-CNCR2820430350>3.0.CO;2-M","article-title":"Combined chemoimmunotherapty for advanced breast cancer: a comparison of BCG and levamisole","volume":"43","author":"Hortobaygi","year":"1979","journal-title":"Cancer."},{"key":"R84-20250603","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(77)92386-8","article-title":"Complications of cancer immunotherapy with levamisole","volume":"309","author":"Parkinson","year":"1977","journal-title":"Lancet."},{"key":"R85-20250603","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ajh.2830090205","article-title":"Mechanisms of levamisole-induced granulocytopenia in breast cancer patients","volume":"9","author":"Vogel","year":"1980","journal-title":"Am J Hematol."},{"key":"R86-20250603","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1309\/AJCPOPQNBP5THKP1","article-title":"Clinicopathologic features of agranulocytosis in the setting of levamisole-tainted cocaine","volume":"133","author":"Czuchlewski","year":"2010","journal-title":"Am J Clin Pathol."},{"key":"R87-20250603","first-page":"303098","article-title":"Recurrent febrile neutropenia and thrombocytopenia in a chronic cocaine user: a case of levamisole induced complications","author":"Martinez","year":"2015","journal-title":"Case Rep Crit Care."},{"key":"R88-20250603","first-page":"3155","article-title":"Study on safety of KW-2-LE-T (Levamisole HCI). Reproductive studies","volume":"10","author":"Ohguro","year":"1982","journal-title":"Yakuri to Chiryo."},{"key":"R89-20250603","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jpba.2016.05.015","article-title":"Teratogenic study of phenobarbital and levamisole on mouse fetus liver tissue using biospectroscopy","volume":"128","author":"Ashtarinezhad","year":"2016","journal-title":"J Pharm Biomed Anal."},{"key":"R91-20250603","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/01.inf.0000234068.25760.97","article-title":"Lack of risk of adverse birth outcomes after deworming in pregnant women","volume":"25","author":"Gyorkos","year":"2006","journal-title":"Pediatr Infect Dis J."},{"key":"R92-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/03009748509102008","article-title":"Antirheumatic drug treatment during pregnancy and lactation","volume":"14","author":"Ostensen","year":"1985","journal-title":"Scand J Rheumatol."},{"key":"R94-20250603","first-page":"48","article-title":"Poisoning of a child by levamisole: evidence by hair testing","volume":"27","author":"Jamey","year":"2015","journal-title":"Toxicol Anal Clin."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000851","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:28:06Z","timestamp":1748971686000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":78,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000851","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"2020-09-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}